A Phase II Study of SGN-15 (cBR96 – Doxorubicin Immunoconjugate) Combined With Gemzar Versus Single-Agent Gemzar in Patients With Advanced Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2011
At a glance
- Drugs Gemcitabine; SGN-15
- Indications Ovarian cancer
- Focus Therapeutic Use
- 21 Oct 2011 Seattle Genetics as company and lead trial centre added as reported by ClinicalTrials.gov.
- 16 Sep 2005 New trial record.